|Series B, 11/2007 |
|Series C, 1/2013 |
Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products based on chemically engineered polymers of hyaluronic acid, a well known polysaccharide widely present in the human body.
Its initial market focus is therapeutic medical devices for rhinosinusitis and osteoarthritis. Carbylanâ€™s proprietary technology enables delivery of biomaterial-based medical devices as injectable liquids that self-polymerize inside the body to form therapeutic implants that covalently bind to tissues at the target delivery site.